GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal
- GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme Therapeutics Inc (NASDAQ: HALO) to gain access to Halozyme's Enhanze drug delivery technology for use against four HIV targets.
- ViiV Healthcare will pay $40 million upfront and up to $175 million in milestones, as well as mid-single-digit royalties on future sales.
- Enhanze technology uses a recombinant human hyaluronidase PH20 enzyme to temporarily break down a barrier under the skin to allow large amounts of fluid to be injected into the subcutaneous space.
- Therefore, drugs that are otherwise given in high doses by intravenous injections could be converted into subcutaneous injectables, offering convenience for patients.
- Plans are underway to initiate the first experiments with the technology by the end of 2021 for investigational, long-acting cabotegravir to prevent HIV, which is currently administered every two months.
- Price Action: HALO shares closed at $42.17 on Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs HIV treatmentBiotech News Health Care Contracts General
